Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum
Status:
Terminated
Trial end date:
2018-05-22
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 2a, open label, proof-of-concept clinical study is to assess the
efficacy and safety of etrasimod (APD334) in patients with Pyoderma Gangrenosum.